Prevalence of hepatitis B antiviral drug resistance variants in North American patients with chronic hepatitis B not receiving antiviral treatment

Journal of Viral Hepatitis

Volumn 24, Issue 11, 2017, Pages 1032-1042

  Lok, A S ^a   Ganova Raeva, L ^b   Cloonan, Y ^c   Punkova, L ^b   Lin, H H S ^c   Lee, W M ^d   Ghany, M G ^e   Lau, Daryl T Y ^f   Chung, Raymond T ^f   Roberts, Lewis R ^f   Smith, Coleman I ^f   Di Bisceglie, Adrian M ^f   Melman, Mauricio ^f   Janssen, L A ^f   Wong, David K ^f   Juan, Joshua ^f   Feld, Jordan ^f   Yim, Colina ^f   Heathcote, Jenny ^f   Perrillo, Robert ^f   Do, Son ^f   Han, Steven Huy B ^f   Tran, Tram T ^f   Terrault, Norah A ^f   Khalili, Mandana ^f   Cooper, Stewart L ^f   Fontana, Robert J ^f   Tsai, Naoky ^f   Fried, Michael W ^f   Patel, Keyur ^f   Evon, Donna ^f   Carithers, Robert C ^f   Shuhart, Margaret ^f   Kowdley, Kris V ^f   Wang, Chia C ^f   Sterling, Richard K ^f   Jake Liang, T ^f   Hoofnagle, Jay H ^f   Doo, Edward ^f   Chang, Kyong Mi ^f   Park, Jang June ^f   Belle, Steven H ^f   Wahed, Abdus ^f   Kleiner, David ^f   more..

^a UNIVERSITY OF MICHIGAN   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f NONE

Author keywords

antiviral treatment; hepatitis B virus; next generation sequencing; nucleos(t)ide analogues; Sanger sequencing

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; ARTICLE; ASIAN; CANADA; CHRONIC HEPATITIS B; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; NONHUMAN; NORTH AMERICAN; PREVALENCE; PRIORITY JOURNAL; SANGER SEQUENCING; UNITED STATES; VIRUS DETECTION; VIRUS TRANSMISSION; YOUNG ADULT; ADOLESCENT; AGED; CLINICAL TRIAL; DNA SEQUENCE; DRUG EFFECT; GENETIC VARIATION; GENETICS; HEALTH SURVEY; HIGH THROUGHPUT SEQUENCING; MULTICENTER STUDY; MUTATION; NORTH AMERICA; VIROLOGY;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENETIC VARIATION; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; NORTH AMERICA; POPULATION SURVEILLANCE; PREVALENCE; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 85021729548     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12732     Document Type: Article

References (17)

1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic Hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546-1555.
2. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137:1593-1608. e1-2.
3. Lok AS, Zoulim F, Locarnini S, Bartholomeusz A, Ghany MG, Pawlotsky JM, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology. 2007;46:254-265.
4. Ono SK, Kato N, Shiratori Y, Kato J, Goto T, Schinazi RF, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing Hepatitis B virus replication and drug resistance. J Clin Invest. 2001;107:449-455.
5. Teo CG, Locarnini SA. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health. Antivir Ther. 2010;15(3 Pt B):445-449.
6. Zhang Q, Liao Y, Cai B, Li Y, Li L, Zhang J, et al. Incidence of natural resistance mutations in naive chronic hepatitis B patients: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2015;30:252-261.
7. Lowe CF, Merrick L, Harrigan PR, Mazzulli T, Sherlock CH, Ritchie G. Implementation of next-generation sequencing for Hepatitis B virus resistance testing and genotyping in a clinical microbiology laboratory. J Clin Microbiol. 2016;54:127-133.
8. Ghany MG, Perrillo R, Li R, Belle SH, Janssen HL, Terrault NA, et al. Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and Hepatitis B virus genotype. Clin Gastroenterol Hepatol. 2015;13:183-192.
9. Ganova-Raeva L, Ramachandran S, Honisch C, Forbi JC, Zhai X, Khudyakov Y. Robust Hepatitis B virus genotyping by mass spectrometry. J Clin Microbiol. 2010;48:4161-4168.
10. Nguyen MH, Garcia RT, Trinh HN, Nguyen HA, Nguyen KK, Nguyen LH, et al. Prevalence of Hepatitis B virus DNA polymerase mutations in treatment-naive patients with chronic hepatitis B. Aliment Pharmacol Ther. 2009;30:1150-1158.
11. Margeridon-Thermet S, Shulman NS, Ahmed A, Shahriar R, Liu T, Wang C, et al. Ultra-deep pyrosequencing of Hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients. J Infect Dis. 2009;199:1275-1285.
12. Vutien P, Trinh HN, Garcia RT, Nguyen HA, Levitt BS, Nguyen K, et al. Mutations in HBV DNA polymerase associated with nucleos(t)ide resistance are rare in treatment-naive patients. Clin Gastroenterol Hepatol. 2014;12:1363-1370.
13. Margeridon-Thermet S, Svarovskaia ES, Babrzadeh F, Martin R, Liu TF, Pacold M, et al. Low-level persistence of drug resistance mutations in Hepatitis B virus-infected subjects with a past history of Lamivudine treatment. Antimicrob Agents Chemother. 2013;57:343-349.
14. Svarovskaia ES, Curtis M, Zhu Y, Borroto-Esoda K, Miller MD, Berg T, et al. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen. J Viral Hepat. 2013;20:131-140.
15. Liu Y, Fung S, Gane EJ, Dinh P, Flaherty JF, Svarovskaia ES, et al. Evaluation of HBV DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF. J Med Virol. 2014;86:1473-1481.
16. Solmone M, Giombini E, Vincenti D, Rozera G, Testa A, Moscetti A, et al. Slow response to entecavir treatment in treatment-naive HBV patients is conditioned by immune response rather than by the presence or selection of refractory variants. Antivir Ther. 2014;19:201-209.
17. WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015. http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/. Accessed June 17, 2017.